{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:05:00Z","timestamp":1787025900124,"version":"build-2736575974"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:p>Background: SMA1 natural history is characterized by early development of chronic respiratory failure. Respiratory interventions in type 1 SMA infants are subject to great practice variability. Nusinersen, has been recently approved in Argentina. The advent of novel treatments has highlighted the need for natural history studies reporting disease progression in type 1 SMA. Objective: To analyze the progression, respiratory interventions and survival based on the type of respiratory support in type 1SMA patients, in a third level pediatric hospital in Argentina. Methods: Cohort of SMA1 patients followed at the Interdisciplinary Program for the Study and Care of Neuromuscular Patients (IPNM). Patient survival was analyzed by using the Kaplan-Meier method. Log-rank test was performed to compare the survival curve for three respiratory intervention groups. Results: 59 patients. Mean age of symptom onset was 2.19 (\u00b11.4) months, age at diagnosis was 3.9 (\u00b12.1) months. Patients developed respiratory failure at 5.82 months (\u00b12.32) and 13.8 months (\u00b15.6) in Type 1B and Type 1C, respectively (p\u200a&lt;\u200a0.001) 53 p were SMA1B. Three copies were found in 1\/6 SMA1C. Respiratory interventions: SRC 23 p (56.1%); SRC\u200a+\u200aNIV 8 p (19.5%); SRC\u200a+\u200aIV 10 p (24.4%). 8 patients were already on invasive ventilation when included in the IPNM. Patients with invasive ventilation showed longer survival. Conclusions: This series provides valuable information on respiratory intervention requirements and life expectancy in children with SMA1 before the implementation of novel treatments that increase the expression of the SMA protein.<\/jats:p>","DOI":"10.3233\/jnd-200508","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T11:03:37Z","timestamp":1599563017000},"page":"453-458","source":"Crossref","is-referenced-by-count":7,"title":["Natural History of Type 1 Spinal Muscular Atrophy in a Series of Argentinian Children"],"prefix":"10.1177","volume":"7","author":[{"given":"V.","family":"Aguerre","sequence":"first","affiliation":[{"name":"Servicio de Neumolog\u00eda, Hospital de Pediatr\u00eda Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Castro","sequence":"additional","affiliation":[{"name":"Hospital de D\u00eda, Hospital de Pediatr\u00eda Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mozzoni","sequence":"additional","affiliation":[{"name":"Servicio de Kinesiolog\u00eda, Hospital de Pediatr\u00eda Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LP.","family":"Gravina","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular, Servicio de Gen\u00e9tica, Hospital de Pediatr\u00eda Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HV.","family":"Araoz","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular, Servicio de Gen\u00e9tica, Hospital de Pediatr\u00eda Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Monges","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital de Pediatr\u00eda Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"7","key":"10.3233\/JND-200508_ref1","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and carrier screening for spinal muscular atrophy","volume":"152","author":"Prior","year":"2010","journal-title":"Am J Med Genet Part A"},{"issue":"2","key":"10.3233\/JND-200508_ref2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"20","key":"10.3233\/JND-200508_ref3","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type 1","volume":"69","author":"Oskoui","year":"2007","journal-title":"Neurology"},{"issue":"18","key":"10.3233\/JND-200508_ref4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.3233\/JND-200508_ref5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.3233\/JND-200508_ref6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"issue":"5","key":"10.3233\/JND-200508_ref9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ppul.23616","article-title":"Physician driven variation in the care of children with spinal muscular atrophy type 1","volume":"52","author":"Oskoui","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.3233\/JND-200508_ref10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"issue":"6","key":"10.3233\/JND-200508_ref11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ppul.21617","article-title":"International survey of physician recommendation for tracheostomy for spinal muscular atrophy Type i","volume":"47","author":"Benson","year":"2012","journal-title":"Pediatr Pulmonol"},{"issue":"10063","key":"10.3233\/JND-200508_ref12","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.3233\/JND-200508_ref13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"10.3233\/JND-200508_ref14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.3233\/JND-200508_ref15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.3233\/JND-200508_ref16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/BF00202811","article-title":"Mapping of two new markers within the smallest interval harboring the spinal muscular atrophy locus by family and radiation hybrid analysis","volume":"93","author":"Brahe","year":"1994","journal-title":"Hum Genet [Internet]"},{"key":"10.3233\/JND-200508_ref17","unstructured":"StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP."},{"issue":"2","key":"10.3233\/JND-200508_ref18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4067\/S0034-98872011000200009","article-title":"Atrofia muscular espinal: Caracterizaci\u00f3n cl\u00ednica, electrofisiol\u00f3gica y molecular de 26 pacientes","volume":"139","author":"Castiglioni","year":"2011","journal-title":"Rev Med Chil"},{"issue":"9","key":"10.3233\/JND-200508_ref19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/gt.2017.68","article-title":"Management of neuromuscular diseases and spinal muscular atrophy in Latin America","volume":"24","author":"Monges","year":"2017","journal-title":"Gene Ther [Internet]"},{"issue":"5","key":"10.3233\/JND-200508_ref20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1542\/peds.2012-2278","article-title":"Survival of patients with spinal muscular atrophy type 1","volume":"131","author":"Gregoretti","year":"2013","journal-title":"Pediatrics"},{"issue":"2","key":"10.3233\/JND-200508_ref22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamapediatrics.2017.4409","article-title":"Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy","volume":"172","author":"Burgart","year":"2018","journal-title":"JAMA Pediatrics"},{"issue":"5","key":"10.3233\/JND-200508_ref23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"18","key":"10.3233\/JND-200508_ref24","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-200508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:30Z","timestamp":1777506570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-200508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":21,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jnd-200508","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}